Menu Back toSession 6: Public and Patient Involvement in Pharmacovigilance
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Pharmacovigilance Strategies Workshop
Session 6: Public and Patient Involvement in Pharmacovigilance
Wendy Huisman, PharmD
- Vigifit, Netherlands
Bianca Mulder, PharmD, MPharm, MSc
- Pharmacovigilance Assessor
- Medicines Evaluation Board, Netherlands
Patient involvement is increasing in more areas of pharmacovigilance. What influence can patient representatives have on decision making? What is the influence of the public by for example social and regular media? How did public involvement influence the communication on the Covid vaccines. Can we ethically “use” influencers/social media as pharmaceutical industry?
Social Media on the Communication of Pfizer on COVID Vaccines
Ihsene Salaa-Lebcira, PhD, MPharm
- Head of Safety Unit in France
- Pfizer, France
Virginie Hivert, PharmD, PhD
- Therapeutic Development Director
- Eurordis-Rare Diseases Europe, France